ATE316782T1 - Neue orale formulierungen für 5-ht4 agonisten oder antagonisten - Google Patents

Neue orale formulierungen für 5-ht4 agonisten oder antagonisten

Info

Publication number
ATE316782T1
ATE316782T1 AT99942892T AT99942892T ATE316782T1 AT E316782 T1 ATE316782 T1 AT E316782T1 AT 99942892 T AT99942892 T AT 99942892T AT 99942892 T AT99942892 T AT 99942892T AT E316782 T1 ATE316782 T1 AT E316782T1
Authority
AT
Austria
Prior art keywords
agonists
antagonists
oral formulations
new oral
new
Prior art date
Application number
AT99942892T
Other languages
English (en)
Inventor
Bruijn Karel De
Guenter Engel
Hans-Juergen Pfannkuche
Michael Thewissen
Christian Vitzling
Othmar Zueger
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE316782(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE316782T1 publication Critical patent/ATE316782T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
AT99942892T 1998-08-21 1999-08-19 Neue orale formulierungen für 5-ht4 agonisten oder antagonisten ATE316782T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds

Publications (1)

Publication Number Publication Date
ATE316782T1 true ATE316782T1 (de) 2006-02-15

Family

ID=27451823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942892T ATE316782T1 (de) 1998-08-21 1999-08-19 Neue orale formulierungen für 5-ht4 agonisten oder antagonisten

Country Status (30)

Country Link
US (4) US20030236183A1 (de)
EP (1) EP1104289B1 (de)
JP (1) JP4048024B2 (de)
KR (1) KR100529659B1 (de)
CN (2) CN1165293C (de)
AT (1) ATE316782T1 (de)
AU (4) AU762829B2 (de)
BG (1) BG65322B1 (de)
BR (1) BR9913135A (de)
CA (1) CA2338794C (de)
CZ (1) CZ300647B6 (de)
DE (1) DE69929703T2 (de)
DK (1) DK1104289T3 (de)
EE (1) EE05054B1 (de)
ES (1) ES2257869T3 (de)
FR (3) FR2782454B1 (de)
HK (1) HK1038179A1 (de)
HR (1) HRP20010123B1 (de)
HU (1) HU228179B1 (de)
ID (1) ID28510A (de)
IL (1) IL141236A0 (de)
IS (1) IS2369B (de)
IT (1) IT1314185B1 (de)
NO (1) NO328756B1 (de)
NZ (1) NZ509832A (de)
PL (2) PL194069B1 (de)
RS (1) RS50104B (de)
SK (1) SK285255B6 (de)
TR (3) TR200400187T2 (de)
WO (1) WO2000010526A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743820B2 (en) 2000-07-07 2004-06-01 University Of Toledo Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
AU2002231627A1 (en) * 2000-11-24 2002-06-03 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
EP1321142A1 (de) * 2001-12-21 2003-06-25 Novartis AG Feste orale Zubereitung mit Tegaserod
EP1598074B1 (de) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Proteinhaltige stabilisierte vorrichtung
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3263117A1 (de) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
EP3332772A1 (de) 2009-10-30 2018-06-13 IX Biopharma Ltd Schnell lösliche feste darreichungsform
WO2013026565A1 (de) 2011-08-20 2013-02-28 Advanced Medical Balloons Trans-analer einlaufkatheter und verfahren zur intermittierenden auslösung einer reflexkoordinierten defäkation
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
DK0472502T3 (da) * 1990-08-24 1995-10-09 Spirig Ag Fremgangsmåde til fremstilling af pellets
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (de) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
EP0804169A4 (de) * 1994-12-01 1998-08-19 Cibus Pharmaceutical Inc Nsaid verabreichung unter verwendung eines gepulverten aus höheren pflanzen gewinnbaren hydrokolloidgummen
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196B1 (fr) * 1996-09-12 1998-10-23 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
NZ505123A (en) * 1997-12-19 2003-07-25 Smithkline Beecham Corp Process for manufacturing bite-dispersion tablets by compressing medicaments and other ingredients into granulates then compressing the granulates and other ingredients into tablets, and the tablets thereof
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (de) * 2001-12-21 2003-06-25 Novartis AG Feste orale Zubereitung mit Tegaserod

Also Published As

Publication number Publication date
ES2257869T3 (es) 2006-08-01
BG65322B1 (bg) 2008-02-29
CN1165293C (zh) 2004-09-08
KR20010079668A (ko) 2001-08-22
FR2782454A1 (fr) 2000-02-25
AU2003248212A1 (en) 2003-10-30
PL200132B1 (pl) 2008-12-31
CN1589906A (zh) 2005-03-09
AU2006200048A1 (en) 2006-02-02
SK285255B6 (sk) 2006-09-07
CZ300647B6 (cs) 2009-07-08
US20130158092A1 (en) 2013-06-20
WO2000010526A2 (en) 2000-03-02
EP1104289A2 (de) 2001-06-06
ID28510A (id) 2001-05-31
KR100529659B1 (ko) 2005-11-21
US20080075773A1 (en) 2008-03-27
HU228179B1 (en) 2013-01-28
FR2782454B1 (fr) 2005-12-02
CA2338794A1 (en) 2000-03-02
WO2000010526A3 (en) 2000-09-08
CA2338794C (en) 2009-01-20
NZ509832A (en) 2003-11-28
US20030236183A1 (en) 2003-12-25
ITMI991826A0 (it) 1999-08-19
NO20010863D0 (no) 2001-02-20
TR200102259T2 (tr) 2002-06-21
DE69929703T2 (de) 2007-02-22
JP2002523351A (ja) 2002-07-30
HUP0103431A3 (en) 2002-02-28
HUP0103431A2 (hu) 2002-01-28
HRP20010123B1 (en) 2010-11-30
TR200100361T2 (tr) 2001-06-21
HK1038179A1 (en) 2002-03-08
EE200100104A (et) 2002-06-17
NO20010863L (no) 2001-03-26
EP1104289B1 (de) 2006-02-01
AU2009200403A1 (en) 2009-02-26
FR2799123A1 (fr) 2001-04-06
BG105257A (en) 2001-11-30
PL346764A1 (en) 2002-02-25
FR2784899A1 (fr) 2000-04-28
DK1104289T3 (da) 2006-05-15
HRP20010123A2 (en) 2002-02-28
IL141236A0 (en) 2002-03-10
NO328756B1 (no) 2010-05-03
IT1314185B1 (it) 2002-12-06
SK2432001A3 (en) 2001-09-11
RS50104B (sr) 2009-01-22
FR2784899B1 (fr) 2001-08-17
ITMI991826A1 (it) 2001-02-19
EE05054B1 (et) 2008-08-15
DE69929703D1 (de) 2006-04-13
CZ2001619A3 (en) 2001-05-16
IS5851A (is) 2001-01-20
PL194069B1 (pl) 2007-04-30
JP4048024B2 (ja) 2008-02-13
US20120071537A1 (en) 2012-03-22
AU762829B2 (en) 2003-07-03
IS2369B (is) 2008-06-15
TR200400187T2 (tr) 2006-11-21
BR9913135A (pt) 2001-05-08
FR2799123B1 (fr) 2005-12-02
CN1323200A (zh) 2001-11-21
YU8701A (sh) 2003-12-31
AU5623299A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
ATE316782T1 (de) Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
ME00298B (me) Farmaceutski preparat
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
EE04450B1 (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
BR9810495A (pt) Composição farmacêutica
BR9911871B1 (pt) derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
HRP20010764B1 (en) Prucalopride oral solution
DK0973505T3 (da) Vandigt farmaceutisk præparat, der omfatter en aktiv ingrediens, som er meget tungt opløselig i vand
YU87501A (sh) Farmaceutski kompleksi
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
MY128958A (en) New oral formulation for 5-ht4 agonists or antagonists.
DK1061938T3 (da) Orale sammensætninger med cytotoksiske proteiner i lav dosis
ECSP993104A (es) Nueva formulacion oral
CR6300A (es) Nueva formulacion oral

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1104289

Country of ref document: EP